Precision Biologics to Reveal Preclinical Efficacy of Novel Tumor-Specific ADC against multiple human cancer types at SITC 2025

BETHESDA, Md., Nov. 5, 2025 /PRNewswire/ – Precision Biologics, Inc. announces in vitro and in vivo efficacy of its novel tumor-specific ADC (PB-vcMMAE-5) against human carcinomas expressing truncated core 2 O-glycans. Recent data for several human cancer types expressing truncated core 2 O-glycans will be presented in a poster at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 7th, 2025, National Harbor, MD, USA.